机构:[1]Hebei Gen Hosp, Shijiazhuang 050051, Hebei, Peoples R China[2]Hebei Med Univ, Grad Sch, Hebei Gen Hosp, Shijiazhuang 050000, Hebei, Peoples R China[3]Suzhou Univ, Suzhou 215000, Jiangsu, Peoples R China[4]Hebei Med Univ, Hosp 4, Shijiazhuang 050000, Hebei, Peoples R China河北医科大学第四医院心血管内科临床科室
Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.
第一作者机构:[1]Hebei Gen Hosp, Shijiazhuang 050051, Hebei, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Li Shu-ren,Tang Zi-jian,Li Zai-han,et al.Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV[J].EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES.2020,39(6):1021-1026.doi:10.1007/s10096-020-03883-y.
APA:
Li, Shu-ren,Tang, Zi-jian,Li, Zai-han&Liu, Xuan.(2020).Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES,39,(6)
MLA:
Li, Shu-ren,et al."Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV".EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 39..6(2020):1021-1026